Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 14/20 | 0.53 |
| ▸ | CTSK | P43235 | 4/20 | 0.53 |
| ▸ | CTSB | P07858 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3874452 | 1.00 | POLB (0.54) | POLBGFERCTSSCTSKCTSB | |
| SCHEMBL3872529 | 0.89 | CTSS (0.54) | POLBCTSSCTSKCTSBCYP2C9 | |
| SCHEMBL3871541 | 0.89 | CTSS (0.54) | POLBCTSSCTSKCTSBCYP2C9 | |
| SCHEMBL346098 | 0.87 | CTSB (0.68) | POLBGFERCTSSCTSKCTSB | |
| SCHEMBL346100 | 0.87 | CTSB (0.68) | POLBGFERCTSSCTSKCTSB | |
| SCHEMBL346509 | 0.85 | CTSB (0.64) | POLBGFERCTSSCTSKCTSB | |
| SCHEMBL346507 | 0.85 | CTSB (0.64) | POLBGFERCTSSCTSKCTSB | |
| SCHEMBL13937580 | 0.84 | CTSS (0.60) | CTSSCTSKCTSBCTSL | |
| SCHEMBL7268474 | 0.83 | POLB (0.76) | POLBGFERCTSSCTSBKDM4E | |
| SCHEMBL7268468 | 0.83 | POLB (0.76) | POLBGFERCTSSCTSBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482448-B2 | Compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482448-B2 | Compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20060189657-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189657-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSB, CTSS, CTSK | POLB 736/4885GFER 3760/4885CTSS 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.